Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Uric acid Stories

2010-06-11 13:40:14

Allopurinol helps kidney function and cuts heart risks A drug commonly used to treat gout may help maintain kidney disease patients' health, according to an analysis appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The research is the first to show that allopurinol treatment in patients with chronic kidney disease (CKD) decreases inflammation, slows the progression of kidney disease, and reduces patients' risk of experiencing a...

2010-06-10 08:00:00

WASHINGTON, June 10 /PRNewswire/ -- The 2010 Gout Attitudes Patient Survey (GAPS), a new study of Americans with gout, released today by Men's Health Network (MHN), sheds light on the painful reality of what life is like for the approximately five million Americans who live with this condition. Of those surveyed, 69 percent described the pain of a gout attack as "miserable," yet a quarter of gout patients feel that those without gout perceive them as overreacting to attacks, and 67 percent...

2010-06-09 05:55:00

TARRYTOWN, N.Y., June 9 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period. Primary Endpoint: Patients who received ARCALYST at a weekly,...

2010-06-08 16:20:00

TARRYTOWN, N.Y., June 8 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Wednesday, June 9, to discuss Phase 3 trial results for ARCALYST® (rilonacept) in the prevention of drug-induced gout flares and in the treatment of acute gout attacks. A press release will be issued tomorrow prior to the call. Teleconference/Webcast Details To participate in...

2010-05-20 07:00:00

NEW YORK, May 20 /PRNewswire/ -- The Gout & Uric Acid Education Society (GUAES) announced today that new survey results reveal that only 1 in 4 (28 percent) of Americans believe that gout, a painful and potentially debilitating form of arthritis that affects 5 million Americans annually, can have a major negative impact on overall health and wellbeing. Yet, if left untreated the chronic health condition can progress to the point of being debilitating, with increased frequency of...

2010-05-13 07:00:00

SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it will present additional data from its completed Phase 2a and Phase 2b monotherapy studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy on June 18th and 19th. The Company will also present additional RDEA594 and allopurinol...

2010-05-07 07:30:00

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the first quarter ended March 31, 2010. "We are pleased to have accomplished a number of very important objectives since our last quarterly update," commented Barry D. Quart, PharmD,...

2010-03-31 15:01:00

SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd...

2010-03-30 13:53:53

Gout incidence lower in women than men, says 52-year follow-up study Researchers from Boston University School of Medicine found that women with serum uric acid levels over 5 mg/dl had a significantly lower risk of developing gout than men. This study, the first to examine the relationship between uric acid levels and gout risk in women, also evaluated purported risk factors for gout and found that increasing age, obesity, hypertension, alcohol use, and diuretic use to be among leading...

2010-03-15 08:41:00

EAST BRUNSWICK, N.J., March 15 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are...